Smiths Medical Offers Innovative Technology that Reduces the Need for
Occlusion De-clotting Medication
The Nexus TKO^® anti-reflux technology is clinically proven to decrease
occlusions in central venous catheters by 58%^1
ST. PAUL, Minn. -- May 14, 2013
Smiths Medical, a leading global medical device manufacturer, announced today
that there is an alternative product that decreases catheter occlusions, a
common problem with IV catheters. Smiths Medical distributes Nexus TKO^® (To
Keep Open) needleless connectors, a solution that can help healthcare
facilities affected by the current supply constraint of the occlusion
de-clotting medication Cathflo^® Activase^® (alteplase)^2.
Nexus TKO^® needleless connectors contain an innovative pressure-activated
anti-reflux technology that prolongs the life of central/peripheral IV lines.
This unique anti-reflux capability helps prevent blood backing up into IV
catheter tips and hubs from patient movement (coughing, sneezing, vomiting),
syringe connection and disconnection, IV bags running dry, syringe plunger
rebound and pressure from ventilators or other hospital equipment. The Nexus
TKO^® needleless connector also has an important clear, rigid, straight fluid
path, which allows a thorough and easy view of effective flush.
“The Nexus TKO^® needleless connectors with anti-reflux technology,
distributed by Smiths Medical, are proven to help maintain catheter patency
and reduce the need for de-clotting medication,” said Jeff Brown, Vice
President Sales & Marketing Smiths Medical, Americas Region. “With the current
supply constraint of Cathflo^® Activase^® (alteplase) for catheter
occlusions, we are pleased to offer customers a simple solution that requires
no change to protocol.”
Blood reflux is one of the most common unintended consequences in IV
therapy^3. Blood reflux can provide an environment for microbes to create
biofilm which can potentially lead to a catheter-related blood stream
infection. Attaching the Nexus TKO^® needleless connector to IV catheters has
proven to reduce peripherally inserted central catheter (PICC) and central
line occlusion by 58%^1, increase peripheral catheter life by over 51%^1, and
decrease peripheral catheter phlebitis and infiltrates by 60%^1. Reducing the
risk of occlusions can result in a decrease in the need for occlusion
de-clotting medication which is currently under a supply constraint.
The Nexus TKO^® needleless connectors are manufactured by Nexus Medical, LLC
and distributed by Smiths Medical in the U.S. and Canada. More product
information can be found by contacting Smiths Medical at 1-800-258-5361 or
1.Jasinsky, RN, BSN, J. Wurster, RN, MSN, Occlusion Reduction and Heparin
Elimination Trial using an Anti-Reflux Device on Peripheral and Central
Intravenous Lines, Intravenous Nurses Society, January/February 2009:
2.Zigulis, Carol. "Product Availability Information for Cathflo® Activase®
(alteplase) 2mg, Activase® (alteplase) 50mg and Activase® (alteplase)
100mg." Letter. 25 March 2013.
3.Hadaway, RN, C, CRNI, Med, Reopening the Pipeline, Nursing 2005, Volume
About Smiths Medical
Smiths Medical www.smiths-medical.com is a leading supplier of specialized
medical devices and equipment for global markets, focusing on the medication
delivery, vital care and safety devices market segments. It is part of Smiths
Group www.smiths.com, a global leader in applying advanced technologies for
markets in threat and contraband detection, energy, medical devices,
communications and engineered components. Smiths Group employs around 22,000
people in more than 50 countries.
Judith Rossi, 781-792-2539
Press spacebar to pause and continue. Press esc to stop.